Correct usage, dosage and medication recommendations of Dacomitinib/Dozerun

Dacomitinib/Dacomitinib (Dacomitinib) is an oral small molecule EGFR targeted inhibitor that is widely used to treat non-small cell lung cancer patients with EGFR sensitive mutations. In clinical practice, the standard recommended dose is 45 mg orally daily until disease progression or intolerable toxicity occurs. This medication regimen not only ensures the effective concentration of the drug, but also maintains controllable safety in most cases.

In terms of taking medication, patients should try to take it orally at the same time every day to maintain stable blood concentration. Dacomitinib can be taken with food or on an empty stomach. It has little effect on absorption, but it needs to be taken with a full glass of water and avoid mixing with drinks such as juice or coffee. If you forget to take the medicine, if the time is short, you can take it as soon as possible. However, if it is close to the next time to take the medicine, you should skip the missed dose and do not take too much at one time.

Special attention needs to be paid to monitoring adverse reactions during medication. Common side effects of dacomitinib include rash, diarrhea, oral mucositis, etc. Some patients may also experience abnormal liver function or pulmonary toxicity. If obvious side effects occur, you should communicate with your doctor in time and adjust the dose or take supportive treatment as needed. In some cases, doctors may recommend reducing the dose to 30 mg or even 15 mg to improve tolerance while ensuring efficacy.

In addition, patients taking the drug should avoid concurrent use of potent CYP2D6 inhibitors or inducers that may affect drug metabolism, so as not to change the blood concentration, affect the efficacy or increase the risk of toxicity. In terms of lifestyle, you should keep a light diet, pay attention to skin care, and regularly review blood routine, liver and kidney function, and imaging evaluations.

In summary, the standard dose of dacomitinib is 45 mg per day Correct medication combined with scientific monitoring is the key to ensuring therapeutic effect and reducing risks.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro